Insights

Innovative Therapeutics Alnylam Pharmaceuticals is at the forefront of RNA interference therapeutics, with multiple FDA-approved medicines and ongoing development of novel therapies, presenting opportunities to integrate complementary treatment options or expand into new disease areas.

Strategic Expansion Recent investments of over $250 million in Massachusetts for expanding and establishing specialized siRNA production facilities indicate a strong capacity for manufacturing, opening avenues for partnerships in large-scale supply chain and distribution channels.

Recent Strategic Initiatives The launch of Alnylam 2030, a five-year growth strategy, highlights the company's focus on sustained innovation and market expansion, suggesting opportunities for collaborations in research, licensing, and commercialization of new RNAi-based products.

Financial Strength With revenue exceeding one billion dollars and significant funding, Alnylam is financially robust, enabling it to pursue aggressive growth strategies, acquisitions, or co-development deals with potential partners interested in biopharma innovations.

Global Presence Operatings across North America, Europe, Asia, and South America, combined with a diverse and talented workforce, present extensive market entry points and collaboration channels for sales expansion into multiple regional healthcare markets.

Similar companies to Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Tech Stack

Alnylam Pharmaceuticals uses 8 technology products and services including SAP SuccessFactors, jsDelivr, Blackline, and more. Explore Alnylam Pharmaceuticals's tech stack below.

  • SAP SuccessFactors
    Applicant Tracking Systems
  • jsDelivr
    Content Delivery Network
  • Blackline
    Corporate Performance Management
  • Siemens
    IT
  • Pantheon
    Platform As A Service
  • Linux
    Programming Languages
  • On-Site
    Real Estate Property Management
  • Flask
    Web Frameworks

Media & News

Alnylam Pharmaceuticals's Email Address Formats

Alnylam Pharmaceuticals uses at least 1 format(s):
Alnylam Pharmaceuticals Email FormatsExamplePercentage
FLast@alnylam.comJDoe@alnylam.com
93%
First.Last@alnylam.comJohn.Doe@alnylam.com
5%
FiLast@alnylam.comJoDoe@alnylam.com
1%
FMiddleLast@alnylam.comJMichaelDoe@alnylam.com
1%

Frequently Asked Questions

Where is Alnylam Pharmaceuticals's headquarters located?

Minus sign iconPlus sign icon
Alnylam Pharmaceuticals's main headquarters is located at 675 West Kendall Street Cambridge, Massachusetts 02142 United States. The company has employees across 6 continents, including North AmericaEuropeAsia.

What is Alnylam Pharmaceuticals's phone number?

Minus sign iconPlus sign icon
You can contact Alnylam Pharmaceuticals's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Alnylam Pharmaceuticals's stock symbol?

Minus sign iconPlus sign icon
Alnylam Pharmaceuticals is a publicly traded company; the company's stock symbol is ALNY.

What is Alnylam Pharmaceuticals's official website and social media links?

Minus sign iconPlus sign icon
Alnylam Pharmaceuticals's official website is alnylam.com and has social profiles on LinkedInCrunchbase.

How much revenue does Alnylam Pharmaceuticals generate?

Minus sign iconPlus sign icon
As of February 2026, Alnylam Pharmaceuticals's annual revenue is estimated to be $1.8B.

What is Alnylam Pharmaceuticals's SIC code NAICS code?

Minus sign iconPlus sign icon
Alnylam Pharmaceuticals's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Alnylam Pharmaceuticals have currently?

Minus sign iconPlus sign icon
As of February 2026, Alnylam Pharmaceuticals has approximately 2.7K employees across 6 continents, including North AmericaEuropeAsia. Key team members include Chief Executive Officer: Y. G.Chief Executive Officer: D. C.Chief Executive Officer: J. M.. Explore Alnylam Pharmaceuticals's employee directory with LeadIQ.

What industry does Alnylam Pharmaceuticals belong to?

Minus sign iconPlus sign icon
Alnylam Pharmaceuticals operates in the Biotechnology Research industry.

What technology does Alnylam Pharmaceuticals use?

Minus sign iconPlus sign icon
Alnylam Pharmaceuticals's tech stack includes SAP SuccessFactorsjsDelivrBlacklineSiemensPantheonLinuxOn-SiteFlask.

What is Alnylam Pharmaceuticals's email format?

Minus sign iconPlus sign icon
Alnylam Pharmaceuticals's email format typically follows the pattern of FLast@alnylam.com. Find more Alnylam Pharmaceuticals email formats with LeadIQ.

How much funding has Alnylam Pharmaceuticals raised to date?

Minus sign iconPlus sign icon
As of February 2026, Alnylam Pharmaceuticals has raised $661M in funding. The last funding round occurred on Sep 09, 2025 for $661M.

When was Alnylam Pharmaceuticals founded?

Minus sign iconPlus sign icon
Alnylam Pharmaceuticals was founded in 2002.

Alnylam Pharmaceuticals

Biotechnology ResearchMassachusetts, United States1001-5000 Employees

SILENCE DISEASE. AMPLIFY LIFE.™

Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them.

Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, five more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases.

We are a global and diverse company of 2,500+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-24), Science Magazine (2018-25), Fast Company (Best Workplaces for Innovators 2020-25) and LinkedIn (2024).

We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America.

See our social media community guidelines: https://bit.ly/2FcRhJy.

Please note: If you wish to report an adverse event or product complaint, please email medinfo@alnylam.com or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861

Fraudulent Recruitment Activity
Be aware of the potential for scams and fraudulent recruitment activity from individuals claiming to represent Alnylam Pharmaceuticals. Alnylam never conducts its interview process via messaging apps, freelance sites, or social media platforms. Alnylam team members only communicate with potential candidates through an official Alnylam email address ending in "@alnylam.com."

Section iconCompany Overview

Headquarters
675 West Kendall Street Cambridge, Massachusetts 02142 United States
Phone number
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
ALNY
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2002
Employees
1001-5000

Section iconFunding & Financials

  • $661M

    Alnylam Pharmaceuticals has raised a total of $661M of funding over 9 rounds. Their latest funding round was raised on Sep 09, 2025 in the amount of $661M.

  • $1B$10B

    Alnylam Pharmaceuticals's revenue is estimated to be in the range of $1B$10B

Section iconFunding & Financials

  • $661M

    Alnylam Pharmaceuticals has raised a total of $661M of funding over 9 rounds. Their latest funding round was raised on Sep 09, 2025 in the amount of $661M.

  • $1B$10B

    Alnylam Pharmaceuticals's revenue is estimated to be in the range of $1B$10B

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.